Boisbriand, Canada Clinical Trials

A listing of Boisbriand, Canada clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 25 clinical trials
Efficacy and Safety of Olaparib Olaparib + Bevacizumab Compared to Bevacizumab + 5-Fluorouracil (FU)

This is an efficacy and safety study of olaparib alone or in combination with bevacizumab being compared to bevacizumab with Fluorouracil (5-FU) in participants with unresectable or metastatic colorectal cancer (CRC) who have not progressed following first-line induction of FOLFOX with bevacizumab. Hypothesis 1 - Olaparib + Bevacizumab is superior …

adenocarcinoma
fluorouracil
oxaliplatin
bevacizumab
colorectal adenocarcinoma
Hopital Cite de la Sante de Laval ( Site 0203)
 (6.2 away) Contact site
  • 10 views
  • 18 Jul, 2021
  • +122 other locations
Antimicrobial Prophylaxis for Skin Colonization With Propionibacterium Acnes in Primary Open Shoulder Surgery

INESS Antibiotic Prophylaxis in Orthopedic Guide recommends the use of Cefazolin at induction for all orthopaedic procedure with implantation of internal fixation device. With the increasing rate of identified P. acnes shoulder surgery infection despite the use of recommended skin preparation and preoperative prophylactic antibiotics, a question arises; Is Cefazolin …

H pital du Sacr -C ur de Montr al
 (8.1 away) Contact site
  • 142 views
  • 20 Jul, 2021
  • +1 other locations
Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity

The researchers are doing the study to see if semaglutide may reduce the risk of having cardiovascular events in patients with overweight or obesity and with prior cardiovascular disease. The participant will either get semaglutide (active medicine) or placebo ("dummy" medicine). Which treatment the participants get is decided by chance. …

cardiovascular disease
overweight or obesity
body mass index
Novo Nordisk Investigational Site
 (7.6 away) Contact site
  • 7712 views
  • 18 Jul, 2021
  • +1164 other locations
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer

The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming …

sentinel lymph node biopsy
invasive carcinoma
adjuvant chemotherapy
immunostimulant
tamoxifen
Hopital de la Cite-de-la-Sante
 (6.2 away) Contact site
  • 591 views
  • 21 Jul, 2021
  • +318 other locations
A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC MK-7339-008/KEYLYNK-008)

The current study will compare pembrolizumab (MK-3475) plus maintenance olaparib, vs. pembrolizumab plus maintenance olaparib placebo for the treatment of squamous NSCLC. The study's 2 primary hypotheses are: Pembrolizumab plus maintenance olaparib is superior to pembrolizumab plus maintenance olaparib placebo with respect to progression-free survival (PFS) per RECIST 1.1 by …

Hopital Cite de la Sante de Laval ( Site 0105)
 (6.2 away) Contact site
  • 119 views
  • 21 Jul, 2021
  • +202 other locations
Pragmatic Randomised Trial of High Or Standard PHosphAte Targets in End-stage Kidney Disease (PHOSPHATE)

During end-stage kidney disease, clinical guidelines suggest reducing elevated phosphate levels in the blood. However, the effect of lowering blood phosphate levels on important patient-centred outcomes has never been tested. This trial will evaluate whether compared to high levels, lowering blood phosphate levels would reduce death or major events due …

renal failure
renal disease
heart disease
diabetes
blood phosphate
Sacre Coeur Hospital
 (8.1 away) Contact site
  • 91 views
  • 15 Jul, 2021
  • +54 other locations
Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG

The primary objective of this study is to evaluate the effectiveness (prevention of thromboembolic events) and safety (major bleeding) of adding oral anticoagulation (OAC) to background antiplatelet therapy in patients who develop new-onset post-operative atrial fibrillation (POAF) after isolated coronary artery bypass graft (CABG) surgery. All patients with a qualifying …

vitamin k
ticagrelor
fibrillation
edoxaban
antiplatelet therapy
H pital du Sacr -C ur de Montr al
 (8.1 away) Contact site
  • 112 views
  • 22 Jul, 2021
  • +79 other locations
Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)

The study is a 64-week randomized, double-masked, multi-center, active-controlled, two-arm study in patients with nAMD (neovascular age related macular degeneration) who have not previously received anti-VEGF (vascular endothelial growth factor) treatment. Patients who consent will undergo screening assessments to evaluate their eligibility based on the inclusion and exclusion criteria.

macular degeneration
retinopathy
fluorescein angiography
choroidal neovascularization
age-related macular degeneration
Novartis Investigative Site
 (5.6 away) Contact site
  • 30 views
  • 21 Jul, 2021
  • +134 other locations
Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)

The purpose of this study is to compare the efficacy of olaparib (MK-7339) plus pembrolizumab (MK-3475) with chemotherapy plus pembrolizumab after induction with first-line chemotherapy plus pembrolizumab in triple negative breast cancer (TNBC). The primary hypotheses are: Olaparib plus pembrolizumab prolongs progression-free survival (PFS) compared with chemotherapy plus pembrolizumab. Olaparib …

breast cancer
carboplatin
cancer
taxane
triple negative breast cancer
CSSS de Laval- Hopital de la Cite de la Sante ( Site 0011)
 (6.2 away) Contact site
  • 241 views
  • 21 Jul, 2021
  • +133 other locations
Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

Study to compare the safety and efficacy of oregovomab versus placebo, administered in combination with specific cycles of a standard six-cycle chemotherapy regimen (paclitaxel and carboplatin), for the treatment of subjects with newly diagnosed advanced ovarian cancer who have undergone optimal debulking.

cancer
adenocarcinoma
tumor debulking
ovarian cancer
epithelial ovarian cancer
City of Health Hospital at Laval (Cit de la Sant de Laval)
 (6.2 away) Contact site
  • 25 views
  • 21 Jul, 2021
  • +78 other locations